Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS).

Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study

De Sanctis, Rita;Santoro, Armando
2020-01-01

Abstract

Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS).
Antineoplastic Agents
Drug Monitoring
Enzyme Inhibitors
Female
Humans
Male
Middle Aged
Progression-Free Survival
Response Evaluation Criteria in Solid Tumors
Treatment Outcome
Ovarian Neoplasms
Pancreatic Neoplasms
Phenylurea Compounds
Pyridines
Sarcoma
Thymoma
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/55114
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact